CoChat

The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p

Open access
Zhang, Xiaoqian, Wen, Long, Chen, Shanwen, Zhang, Junling, Ma, Yongchen, Hu, Jianwen, Yue, Taohua, Wang, Jingui, Zhu, Jing, Bu, Dingfang, Wang, Xin · 2020 · Cancer Cell International

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Background: Long noncoding RNAs (lncRNAs) have been shown to participate in multiple biological processes and confer drug resistance. However, it remains unclear whether lncRNAs are involved in conferring cetuximab resistance in colorectal cancer (CRC) cells. Methods: Cell Counting Kit-8 (CCK-8) assays were performed to assess the sensitivity of CRC cell lines to cetuximab treatment. We incubated Caco-2 cells, which are partially responsive to cetuximab, with increasing concentrations of cetuximab for approximately 6 months to generate Caco-2 cetuximab-resistant (Caco-2 CR) cells. Microarray analysis comparing Caco-2 CR with Caco-2 cells was used to identify lncRNAs that were potentially related to cetuximab resistance. Caco-2 cells were stably transduced with cetuximab resistance-associated RNA transcript 16 (CRART16) or an empty vector using lentiviral infection; the cells were designated Caco-2-CRART16 and Caco-2-NC, respectively, and were analyzed with RNA sequencing (RNA-seq). Quantitative real-time PCR (qRT-PCR) was performed to investigate RNA expression. Flow cytometry and TUNEL assays were used to assess apoptosis levels induced by cetuximab. The cell cycle, stemness biomarkers and membrane proteins of CRC cells were assessed via flow cytometry. RNA fluorescence in situ hybridization (FISH) was used to examine CRART16 localization and expression. Bioinformatics analysis was performed to predict the potential mechanism of CRART16, which was further validated by a dual-luciferase reporter assay. Differences in measurement data were compared using Student’s t test, one-way ANOVA followed by Dunnett’s test and two-way ANOVA. Results: The novel lncRNA CRART16 was upregulated in Caco-2 CR cells. CRART16 overexpression reversed the effects of cetuximab on cell viability and reduced cetuximab-induced apoptosis. Meanwhile, CRART16 overexpression led to increases in the proportion of CD44+/CD133+ cells. In addition, CRART16 acts as a competing endogenous RNA (ceRNA) for miR-371a-5p to regulate V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 3 (ERBB3) expression. MiR-371a-5p mimics counteracted the cetuximab resistance induced by CRART16 overexpression. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that after CRART16 was overexpressed, the resulting differentially expressed mRNAs were mainly enriched in the MAPK signaling pathway. Conclusions: CRART16 overexpression may contribute to cetuximab resistance through the miR-371a-5p/ERBB3/MAPK pathway. Additionally, CRART16 contributes to the acquisition of stemness properties.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12935-020-1155-9

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Phenotypic characteristics of Caco-2 and Caco-2 CR cells. a The sensitivity of a panel of CRC cell lines (HCT116, SW620, Caco-2 and HCT8) to cetuximab treatment was assessed by CCK8 assays. CRC cells were incubated with graded concentrations (0–200 μg/ml) of cetuximab for 48 h. Six replicates were used for each concentration, and the experiment was repeated at least three times. Data are presented as mean ± SD. b Cell viability was assessed by CCK8 assays in Caco-2 and Caco-2 CR cells treated with various concentrations of cetuximab (0–200 μg/ml) for 48 h. Each concentration had six replicates, and the experiment was repeated at least three times. Data are presented as mean ± SD. **P < 0.01 by two-way ANOVA. c Flow cytometry was performed in Caco-2 and Caco-2 CR cells with cetuximab treatment (100 μg/ml and 200 μg/ml) for 48 h. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by Student’s t test. ##P < 0.01 by one-way ANOVA followed by Dunnett’s test. d Caco-2 and Caco-2 CR cells were treated with or without 200 μg/ml cetuximab (CTX) for 48 h. Apoptosis was detected by a TUNEL assay. Scale bar = 100 μm. e The cell cycle was assessed by flow cytometry in Caco-2 and Caco-2 CR cells after 48 h of treatment with cetuximab (200 μg/ml). All experiments were repeated three times, and data are presented as mean ± SD. */#P < 0.05, **/##P < 0.01 by Student’s t test. f The percentage of EGFR-, ERBB3-, and c-MET-positive cells and the MFI were determined by GALLIOUS flow cytometry in Caco-2 and Caco-2 CR cells. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **P < 0.01 by Student’s t test. g Flow cytometry analysis showed the expression of stemness biomarkers of CRC cells, CD44 and CD133, in Caco-2 and Caco-2 CR cells. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05 by Student’s t test
Fig. 1 Phenotypic characteristics of Caco-2 and Caco-2 CR cells. a The sensitivity of a panel of CRC cell lines (HCT116, SW620, Caco-2 and HCT8) to cetuximab treatment was assessed by CCK8 assays. CRC cells were incubated with graded concentrations (0–200 μg/ml) of cetuximab for 48 h. Six replicates were used for each concentration, and the experiment was repeated at least three times. Data are presented as mean ± SD. b Cell viability was assessed by CCK8 assays in Caco-2 and Caco-2 CR cells treated with various concentrations of cetuximab (0–200 μg/ml) for 48 h. Each concentration had six replicates, and the experiment was repeated at least three times. Data are presented as mean ± SD. **P < 0.01 by two-way ANOVA. c Flow cytometry was performed in Caco-2 and Caco-2 CR cells with cetuximab treatment (100 μg/ml and 200 μg/ml) for 48 h. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by Student’s t test. ##P < 0.01 by one-way ANOVA followed by Dunnett’s test. d Caco-2 and Caco-2 CR cells were treated with or without 200 μg/ml cetuximab (CTX) for 48 h. Apoptosis was detected by a TUNEL assay. Scale bar = 100 μm. e The cell cycle was assessed by flow cytometry in Caco-2 and Caco-2 CR cells after 48 h of treatment with cetuximab (200 μg/ml). All experiments were repeated three times, and data are presented as mean ± SD. */#P < 0.05, **/##P < 0.01 by Student’s t test. f The percentage of EGFR-, ERBB3-, and c-MET-positive cells and the MFI were determined by GALLIOUS flow cytometry in Caco-2 and Caco-2 CR cells. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **P < 0.01 by Student’s t test. g Flow cytometry analysis showed the expression of stemness biomarkers of CRC cells, CD44 and CD133, in Caco-2 and Caco-2 CR cells. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05 by Student’s t testCC BY · PubMed Central
Fig. 2 CRART16 is upregulated in Caco-2 CR. a Scatter plots show the difference in the expression of lncRNAs between Caco-2 and Caco-2 CR cells. Red dots above the red line indicate significantly upregulated lncRNAs, whereas green dots below the green line indicate significantly downregulated lncRNAs. b The expression of the CRART16 was detected in a panel of CRC cell lines (Caco-2, Caco-2 CR, HCT116, SW620 and HCT8) by qRT-PCR. GAPDH was used as an internal control. All experiments were repeated three times, and data are presented as mean ± SD. c The transfection efficiency and morphology of Caco-2-CRART16 and Caco-2-NC cells were viewed by bright field and fluorescence microscopy. Scale bar = 100 μm. d Transfection efficiency of the lncRNA CRART16 was detected in Caco-2-CRART16 and Caco-2-NC cells by qRT-PCR. GAPDH was used as an internal control. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by Student’s t test
Fig. 2 CRART16 is upregulated in Caco-2 CR. a Scatter plots show the difference in the expression of lncRNAs between Caco-2 and Caco-2 CR cells. Red dots above the red line indicate significantly upregulated lncRNAs, whereas green dots below the green line indicate significantly downregulated lncRNAs. b The expression of the CRART16 was detected in a panel of CRC cell lines (Caco-2, Caco-2 CR, HCT116, SW620 and HCT8) by qRT-PCR. GAPDH was used as an internal control. All experiments were repeated three times, and data are presented as mean ± SD. c The transfection efficiency and morphology of Caco-2-CRART16 and Caco-2-NC cells were viewed by bright field and fluorescence microscopy. Scale bar = 100 μm. d Transfection efficiency of the lncRNA CRART16 was detected in Caco-2-CRART16 and Caco-2-NC cells by qRT-PCR. GAPDH was used as an internal control. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by Student’s t testCC BY · PubMed Central
Fig. 3 CRART16 promotes cetuximab resistance and contributes to the acquisition of stemness properties of CRC cells. a CCK8 assay was performed to assess the cell viability of Caco-2-CRART16 and Caco-2-NC cells treated with graded concentrations of cetuximab (0–200 μg/ml) for 48 h. Each concentration had six replicates, and the experiment was repeated at least three times. Data are presented as mean ± SD. **P < 0.01 by two-way ANOVA. b Flow cytometry was performed in Caco-2-CRART16 and Caco-2-NC cells with cetuximab treatment (100 μg/ml and 200 μg/ml) for 48 h. All experiments were repeated three times, and data are presented as mean ± SD. **/##P < 0.01 by Student’s t test. c Caco-2-CRART16 and Caco-2-NC cells were treated with 200 μg/ml cetuximab for 48 h. Apoptosis was detected by a TUNEL assay. Scale bar = 100 μm. d The cell cycle was assessed by flow cytometry in Caco-2-CRART16 and Caco-2-NC cells after 48 h of treatment with cetuximab (200 μg/ml). All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **/##P < 0.01 by Student’s t test. e The percentage of EGFR-, ERBB3-, and c-MET-positive cells and the MFI were determined by a GALLIOUS flow cytometer in Caco-2-CRART16 and Caco-2-NC cells. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by Student’s t test. f Flow cytometry analysis showed the expression of stemness biomarkers in CRC cells, CD44 and CD133, in Caco-2-CRART16 and Caco-2-NC cells. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05 by Student’s t test
Fig. 3 CRART16 promotes cetuximab resistance and contributes to the acquisition of stemness properties of CRC cells. a CCK8 assay was performed to assess the cell viability of Caco-2-CRART16 and Caco-2-NC cells treated with graded concentrations of cetuximab (0–200 μg/ml) for 48 h. Each concentration had six replicates, and the experiment was repeated at least three times. Data are presented as mean ± SD. **P < 0.01 by two-way ANOVA. b Flow cytometry was performed in Caco-2-CRART16 and Caco-2-NC cells with cetuximab treatment (100 μg/ml and 200 μg/ml) for 48 h. All experiments were repeated three times, and data are presented as mean ± SD. **/##P < 0.01 by Student’s t test. c Caco-2-CRART16 and Caco-2-NC cells were treated with 200 μg/ml cetuximab for 48 h. Apoptosis was detected by a TUNEL assay. Scale bar = 100 μm. d The cell cycle was assessed by flow cytometry in Caco-2-CRART16 and Caco-2-NC cells after 48 h of treatment with cetuximab (200 μg/ml). All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **/##P < 0.01 by Student’s t test. e The percentage of EGFR-, ERBB3-, and c-MET-positive cells and the MFI were determined by a GALLIOUS flow cytometer in Caco-2-CRART16 and Caco-2-NC cells. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by Student’s t test. f Flow cytometry analysis showed the expression of stemness biomarkers in CRC cells, CD44 and CD133, in Caco-2-CRART16 and Caco-2-NC cells. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05 by Student’s t testCC BY · PubMed Central
Fig. 4 CRAT16 functions as a miR-371a-5p sponge. a FISH analysis of CRART16 in Caco-2 and Caco-2 CR cells (nuclei were stained with DAPI). Scale bar = 25 μm. b MiRNA heatmap shows the top differentially expressed miRNAs in Caco-2-CRART16 cells versus Caco-2-NC cells. c Schematic diagram of the predicted binding sites between lncRNA CRAT16 and miR-371a-5p. d The expression of miR-371a-5p was detected in Caco-2, Caco-2 CR, Caco-2-CRART16 and Caco-2-NC cells by qRT-PCR. U6 was used as an internal control. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **P < 0.01 by Student’s t test. e Dual-luciferase reporter assays in 293T cells. The relative luciferase activity was measured after cotransfection with miR-371a-5p mimics or NC and either the pmiR-RB-Report™-CRART16-WT vector or the empty vector. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by Student’s t test. f The expression of miR-371a-5p was detected by qRT-PCR in Caco-2-CRART16 cells after transfection of miR-371a-5p mimics. U6 was used as an internal control. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **P < 0.01 by Student’s t test. g CCK8 assay was performed to assess the cell viability of Caco-2-CRART16 cells after miR-371a-5p overexpression with graded concentrations of cetuximab (0–200 μg/ml) for 48 h. Each concentration had six replicates, and the experiment was repeated at least three times. Data are presented as mean ± SD. **P < 0.01 by two-way ANOVA
Fig. 4 CRAT16 functions as a miR-371a-5p sponge. a FISH analysis of CRART16 in Caco-2 and Caco-2 CR cells (nuclei were stained with DAPI). Scale bar = 25 μm. b MiRNA heatmap shows the top differentially expressed miRNAs in Caco-2-CRART16 cells versus Caco-2-NC cells. c Schematic diagram of the predicted binding sites between lncRNA CRAT16 and miR-371a-5p. d The expression of miR-371a-5p was detected in Caco-2, Caco-2 CR, Caco-2-CRART16 and Caco-2-NC cells by qRT-PCR. U6 was used as an internal control. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **P < 0.01 by Student’s t test. e Dual-luciferase reporter assays in 293T cells. The relative luciferase activity was measured after cotransfection with miR-371a-5p mimics or NC and either the pmiR-RB-Report™-CRART16-WT vector or the empty vector. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by Student’s t test. f The expression of miR-371a-5p was detected by qRT-PCR in Caco-2-CRART16 cells after transfection of miR-371a-5p mimics. U6 was used as an internal control. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **P < 0.01 by Student’s t test. g CCK8 assay was performed to assess the cell viability of Caco-2-CRART16 cells after miR-371a-5p overexpression with graded concentrations of cetuximab (0–200 μg/ml) for 48 h. Each concentration had six replicates, and the experiment was repeated at least three times. Data are presented as mean ± SD. **P < 0.01 by two-way ANOVACC BY · PubMed Central
Fig. 5 CRART16 modulates ERBB3 expression in a miR-371a-5p-dependent manner. a The expression of ERBB3, ATP8B1, KAT6A, FKTN, UCHL5, NUF2 and RPS6KA3 was detected by qRT-PCR after lncRNA CRART16 overexpression. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by two-way ANOVA. b Schematic diagram of the predicted binding sites between ERBB3 and miR-371a-5p. c Dual-luciferase reporter assays in 293T cells. The relative luciferase activity was measured after cotransfection with miR-371a-5p mimics or miR-NC and either the pmiR-RB-Report™-ERBB3 3′ UTR-WT vector or the empty vector. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by Student’s t test. d The expression of ERBB3 was detected in Caco-2-CRART16 cells after miR-371a-5p knockdown. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **P < 0.01 by Student’s t test. e The percentage of ERBB3-positive cells and the MFI were determined by GALLIOUS flow cytometry in Caco-2-CRART16 cells after miR-371a-5p knockdown. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **P < 0.01 by Student’s t test
Fig. 5 CRART16 modulates ERBB3 expression in a miR-371a-5p-dependent manner. a The expression of ERBB3, ATP8B1, KAT6A, FKTN, UCHL5, NUF2 and RPS6KA3 was detected by qRT-PCR after lncRNA CRART16 overexpression. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by two-way ANOVA. b Schematic diagram of the predicted binding sites between ERBB3 and miR-371a-5p. c Dual-luciferase reporter assays in 293T cells. The relative luciferase activity was measured after cotransfection with miR-371a-5p mimics or miR-NC and either the pmiR-RB-Report™-ERBB3 3′ UTR-WT vector or the empty vector. All experiments were repeated three times, and data are presented as mean ± SD. **P < 0.01 by Student’s t test. d The expression of ERBB3 was detected in Caco-2-CRART16 cells after miR-371a-5p knockdown. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **P < 0.01 by Student’s t test. e The percentage of ERBB3-positive cells and the MFI were determined by GALLIOUS flow cytometry in Caco-2-CRART16 cells after miR-371a-5p knockdown. All experiments were repeated three times, and data are presented as mean ± SD. *P < 0.05, **P < 0.01 by Student’s t testCC BY · PubMed Central
Fig. 6 Schematic diagram of the mechanism of CRART16 in cetuximab resistance
Fig. 6 Schematic diagram of the mechanism of CRART16 in cetuximab resistanceCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 37

Metadata

Authors
Zhang, X., Wen, L., Chen, S., Zhang, J., Ma, Y., Hu, J., Yue, T., Wang, J., Zhu, J., Bu, D., & Wang, X.
Affiliations
Peking University First Hospital (CN)
Corresponding author
Wang, Xin
Venue
Cancer Cell International
Published
2020-03-04
Volume
20
Issue
1
Pages
68-68
ISSN
1475-2867 (ISSN-L)
OpenAlex
W3012275406
Cited by
35
References
48
Citations by year
2026: 1 · 2025: 3 · 2024: 5 · 2023: 2 · 2022: 10 · 2021: 12 · 2020: 1
FWCI
2.14
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Cell International (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
long non-coding RNA, cetuximab resistance, colorectal cancer, HER3, competing endogenous RNA, anti-EGFR therapy, apoptosis, cell cycle, cancer stemness, drug resistance, Caco-2 cells, lncRNA-miRNA interaction, cell invasion

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p. https://app.cochat.ai/papers/10.1186/s12935-020-1155-9
The paper
Zhang, X., Wen, L., Chen, S., Zhang, J., Ma, Y., Hu, J., Yue, T., Wang, J., Zhu, J., Bu, D., & Wang, X. (2020). The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p. Cancer Cell International. https://doi.org/10.1186/s12935-020-1155-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.